Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Thirteen brokerages give Elanco an average rating of "Moderate Buy" (9 buys, 1 strong buy, 2 holds, 1 sell) with a mean 12‑month price target of $27.90, implying upside from current levels.
• Elanco beat the most recent quarter's EPS estimate ($0.13 vs. $0.11) and delivered 12.2% revenue growth to $1.14 billion, and has set Q1 2026 guidance of $0.33–$0.36 EPS and FY2026 guidance of $1.00–$1.06 (analysts forecast ~1.03 EPS).
• The stock opened at $21.81 (52‑week range $9.32–$27.72) with a $10.85 billion market cap and very high institutional ownership (~97.5%), suggesting active institutional interest despite recent share volatility.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has received an average rating of "Moderate Buy" from the thirteen brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $27.90.

ELAN has been the subject of several research analyst reports. Leerink Partners boosted their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an "outperform" rating in a research report on Tuesday, February 24th. KeyCorp boosted their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an "overweight" rating in a research report on Wednesday, February 25th. Weiss Ratings upgraded shares of Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research report on Monday. JPMorgan Chase & Co. boosted their price objective on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Thursday, February 19th. Finally, Citigroup assumed coverage on shares of Elanco Animal Health in a research report on Wednesday, April 15th. They set a "buy" rating and a $30.00 price objective for the company.

Elanco Animal Health Stock Down 1.5%

Shares of ELAN opened at $21.81 on Thursday. Elanco Animal Health has a one year low of $9.32 and a one year high of $27.72. The company has a market cap of $10.85 billion, a P/E ratio of -45.44, a P/E/G ratio of 2.82 and a beta of 1.88. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08. The firm has a 50 day simple moving average of $23.92 and a two-hundred day simple moving average of $23.24.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the business earned $0.14 earnings per share. The company's revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Research analysts forecast that Elanco Animal Health will post 1.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Parallel Advisors LLC increased its holdings in shares of Elanco Animal Health by 5.9% during the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company's stock worth $160,000 after buying an additional 392 shares in the last quarter. Lazard Asset Management LLC increased its holdings in shares of Elanco Animal Health by 0.6% during the fourth quarter. Lazard Asset Management LLC now owns 72,065 shares of the company's stock worth $1,631,000 after buying an additional 425 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its holdings in shares of Elanco Animal Health by 0.4% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company's stock worth $2,516,000 after buying an additional 428 shares in the last quarter. Meeder Advisory Services Inc. increased its holdings in shares of Elanco Animal Health by 4.8% during the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company's stock worth $254,000 after buying an additional 510 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC increased its holdings in shares of Elanco Animal Health by 4.2% during the first quarter. Fifth Third Wealth Advisors LLC now owns 14,273 shares of the company's stock worth $342,000 after buying an additional 579 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.